Vasoconstriction and defective placental angiogenesis are key factors in the etiology of preeclampsia. Prolactin levels are elevated in maternal blood throughout pregnancy and the human decidua produces prolactin that is transported to the amniotic fluid. Prolactin is cleaved to yield vasoinhibins, a family of peptides that inhibit angiogenesis and nitric oxidedependent vasodilation. Here, we conducted a case-control study to measure vasoinhibins in serum, urine, and amniotic fluid obtained from women with severe preeclampsia. We show that all three biological fluids contained significantly higher levels of vasoinhibins in preeclamptic women than in normal pregnant women. Amniotic fluid from preeclamptic women, but not from normal women, inhibited vascular endothelial growth factor-induced endothelial cell proliferation and nitric oxide synthase activity in cultured endothelial cells, and these actions were reversed by antibodies able to neutralize the effects of vasoinhibins. Furthermore, amniotic fluid does not appear to contain neutral prolactin-cleaving proteases, suggesting that vasoinhibins in amniotic fluid are derived from prolactin cleaved within the placenta. Also, cathepsin-D in placental trophoblasts cleaved prolactin to vasoinhibins, and its activity was higher in placental trophoblasts from preeclamptic women than from normal women. Importantly, birth weight of infants in preeclampsia inversely correlated with the extent to which the corresponding AF inhibited endothelial cell proliferation and with its concentration of prolactin þ vasoinhibins. These data demonstrate that vasoinhibins are increased in the circulation, urine, and amniotic fluid of preeclamptic women and suggest that these peptides contribute to the endothelial cell dysfunction and compromised birth weight that characterize this disease.
Preeclampsia affects about 5% of all pregnancies and results in substantial maternal and neonatal morbidity and mortality. 1 Although the etiology of preeclampsia remains unclear, the syndrome may be initiated by placental factors causing endothelial cell dysfunction at the fetomaternal interface and in the systemic maternal circulation.
1,2 Poor placental and decidual vascularization results in inadequate placental development and may restrict fetal growth, whereas dysregulation of the maternal vascular endothelium leads to hypertension and proteinuria-the clinical manifestations of preeclampsia. 1, 2 Vascular endothelial growth factor (VEGF) is a major promoter of angiogenesis and vasodilation in the placenta. 2 The actions of VEGF are partially mediated by the production of endothelium-derived nitric oxide (NO), 3 a potent vasorelaxant that regulates systemic blood pressure, vascular permeability, and angiogenesis. 4 Decreased levels of VEGF and NO are seen not only during preeclampsia, but also before the onset of clinical symptoms. [5] [6] [7] [8] Moreover, interference with placental VEGF and NO compromises normal angiogenesis and leads to a poorly perfused fetoplacental unit, hypertension, proteinuria, and fetal growth restriction, 6, [9] [10] [11] suggesting that blockage of VEGF and NO has a causal role in preeclampsia.
Prolactin (PRL), originally identified as a lactotrophic hormone secreted by the pituitary gland, is also synthesized in numerous extrapituitary tissues, including the decidual cells in the uterus, from which it is transported to the amniotic fluid (AF) where it reaches high levels. 12, 13 Proteolysis of PRL by cathepsin-D or by matrix metalloproteases produces vasoinhibins, a family of peptides that act on endothelial cells to inhibit vasodilation and angiogenesis and to promote apoptosis-mediated vascular regression. 14 Vasoinhibins suppress VEGF-induced NO synthase (NOS) activity in endothelial cells, and exogenous NO reverses inhibition by vasoinhibins of VEGF-induced endothelial cell proliferation and acetylcholine-induced vasodilation. 15 The increased presence of PRL in maternal blood throughout pregnancy 16 and its synthesis by decidual cells, coupled to the fact that vasoinhibins impair VEGF-dependent activation of endothelial NOS, angiogenesis, and vasodilation, suggest that vasoinhibins may play a role in preeclampsia. The purpose of this study was to determine whether vasoinhibins are present in the serum, urine, and AF from patients with severe preeclampsia, and if they could reduce the proangiogenic actions of VEGF, inhibit NOS activity, and contribute to reducedbirth weight.
MATERIALS AND METHODS Study Population
The study encompassed 21 pregnant women without history of diabetes mellitus, thyroid, liver, or chronic renal disease attending the Obstetrics Outpatient Department of the 'Instituto Nacional de Perinatología Isidro Espinosa de los Reyes' in Mexico City. All women provided written, informed consent before collection of samples. The Institutional Review Board approved the collection and use of the samples, and the study was conducted according to the third edition of the Guidelines on the Practice of Ethical Committees in Medical Research issued by the Royal College of Physicians of London. The control group included eight clinically healthy, normotensive women between 18 and 38 years of age, with full-term (Z36 weeks of gestation) uneventful pregnancies (all singleton), who were undergoing cesarean section for obstetric reasons. The preeclamptic group included 13 previously normotensive women, 16-40 years old with severe preeclampsia diagnosed between 28 and 39 weeks of gestation (all singleton), who were admitted to our institution between 24 and 72 h after initiation of symptoms (rapid weight gain, headache, and dizziness). They underwent cesarean section immediately after blood pressure was brought under control by medical treatment (methyldopa, diuretics, and diphenylhydantoin). Severe preeclampsia was defined as persistent blood pressure of Z150/110 mm Hg and proteinuria of Z3 g in a 24-h urine sample or 43 þ (300 mg/dl) as determined by dipstick testing. All preeclamptic women became normotensive within 2 weeks after the end of pregnancy. In addition, venous blood and urine samples were collected from a group of six volunteer, age-matched, non-pregnant women.
Determination of PRL, Vasoinhibins, and VEGF Venous blood, urine, and AF samples were obtained immediately before the cesarean section and centrifuged at 3000 r.p.m. for 20 min; aliquots of the supernatants were stored frozen at À701C. PRL was quantified using an immunoradiometric assay kit (IRMA) (Diagnostic Products Corporation, Los Angeles, CA, USA), with a detection limit of 1.5 ng/ml and intra-and inter-assay coefficients of variance of o4 and o7.8%, respectively. Vasoinhibins were immunoprecipitated from 750 ml of serum or urine with 3 ml of anti-human PRL antiserum obtained and characterized as reported 17 using the previously published technique. 18 The immunoprecipitates were subjected to SDS-PAGE on a 12% acrylamide gel under reducing conditions, transferred to nitrocellulose membranes, and probed with 4.2 mg/ml antihuman PRL monoclonal antibodies (mAb 5602, Diagnostic Biochem Canada Inc., London, Ontario, Canada) that react with the N terminus of PRL. 19 To assay for vasoinhibins in AF, 35 ml of AF was processed in 15% SDS-PAGE western blots probed with the mAb 5602. Detection of immunoreactive proteins in serum and urine was performed with the SuperSignal West Femto Maximum Sensitivity Substrate kit (Pierce Biotechnology Inc., Rockford, IL, USA); whereas, in the AF they were revealed with the alkaline phosphatase secondary antibody kit (Bio-Rad Laboratories, Hercules, CA, USA). Optical density values were determined using 1D image analysis software, version 3.5 (Eastman Kodak Company, Rochester, NY, USA). Human PRL was obtained from the National Hormone and Pituitary Program (NHPP, Torrance, CA, USA), and human vasoinhibins were generated using a baculovirus expression system. 20 The AF levels of VEGF were quantified with an enzyme-linked immunosorbent assay (Biosource International Inc., Camarillo, CA, USA). The assay recognizes both natural and recombinant human VEGF-165 with a sensitivity of 5 pg/ml and has intra-and interassay coefficients of variance of o4.7 and o8.1%, respectively.
Endothelial Cell Culture and Proliferation Assay
Bovine umbilical vein endothelial cells (BUVEC) were obtained as described previously. 21 The cells were cultured in F12K medium with 10% fetal bovine serum and 50 U/ml penicillin/streptomycin. To test the proliferative effects of normal and preeclamptic AF, BUVEC were seeded at 5000 cells/cm 2 and cultured in the presence and absence of 10 ng/ml VEGF (a gift from Genentech, South San Francisco, CA, USA), alone or together with increasing concentrations of each AF, and with either 0.1 mg/ml of purified anti-human PRL antibodies or control antibodies. The antibodies were purified from rabbit anti-human PRL antiserum or normal rabbit serum on a protein A Sepharose column (Sigma, St Louis, MO, USA) as described. 22 15 
PRL Cleavage by Proteases in AF and Placental Trophoblasts
The activity of enzymes that cleave PRL to vasoinhibins was assessed in normal and preeclamptic AF by incubating 10 ml of each AF sample with 10 ml of pH 7 incubation buffer (0.05 M Tris-HCl, 0.15 M NaCl, and 0.01 M CaCl 2 ) or of 0.1 M citrate-phosphate buffer pH 5.5, containing 0.15 M NaCl, for 72 h at 371C. Incubation at acid pH was carried out in the absence or presence of the cathepsin-D inhibitor pepstatin-A (final concentration was 1.4 mM). The reaction was stopped by the addition of reducing Laemmli buffer followed by boiling the samples for 5 min and fractionating on 15% SDS-PAGE western blots. Procathepsin-D and cathepsin-D were analyzed in 20 ml of AF using 12% SDS-PAGE western blots probed with 0.8 mg/ml anti-cathepsin-D polyclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Placental trophoblasts were obtained by stripping the amnion from the chorio-decidua, cutting the basal plate, and excising a region from the central area of the placenta. Trophoblasts were stored at À801C until lysed with a glass homogenizer in cold lysis buffer (0.5% Nonidet P-40, 0.1% SDS, 50 mM Tris, 150 mM NaCl, 1 mg/ml aprotinin, and 100 mg/ml phenylmethylsulfonyl fluoride, pH 7), followed by homogenization by a Polytron PT 10-35 (Kinematica, Switzerland) for 10 s at a setting of 4. Cleavage of PRL by trophoblasts was determined by incubating 200 ng of human PRL standard in 5 ml of 0.1 M Tris (pH 7.4) mixed with 5 ml of different concentrations of trophoblast lysate protein and 10 ml of 0.1 M citrate buffer pH 4.2 containing 0.15 M NaCl. Cleaved-PRL products were investigated on reducing 15% SDS-PAGE western blots.
Statistical Analysis
Data are presented as mean7s.e.m. As appropriate, Student's unpaired t-test or one-way ANOVA followed by Tukey's test to compare individual means was used for statistical comparisons. Correlations between variables were analyzed using the Spearman's correlation coefficient. The significance level was set at 5%.
RESULTS
PRL and Vasoinhibins in Serum, Urine, and AF PRL levels in serum, urine, and AF as determined by IRMA, were within the range of values previously reported at the end of gestation.
16,24,25 PRL concentrations in serum were 60-fold higher than in urine, and 4-fold lower than in AF ( Figure 1 ). In preeclamptic women, the mean concentration of PRL in serum, urine, and AF was higher than but not statistically different from levels in normal pregnant women ( Figure 1 ). Because all bioactive vasoinhibins contain the N terminus of PRL, 14 the presence of vasoinhibins in serum and urine was investigated by immunoprecipitation with antihuman PRL antiserum followed by western blots using a mAb that selectively recognizes the N-terminal region of PRL ( Figure 2 ). As expected, the N-terminal mAb reacted with the standard preparations of full-length 23 kDa PRL, 16, and 14 kDa vasoinhibins. In the serum samples, the light chain of immunoglobulin molecules, which has a mass of approximately 25 kDa, created an artifact that interfered with the detection of the full-length 23 kDa PRL. Nevertheless, serum contained immunoreactive proteins of 18, 16, and 14 kDa (Figure 2a ) that may correspond to vasoinhibins, which vary in size between 12 and 18 kDa and contain the N-terminal end of PRL.
14 The vasoinhibin-like immunoreactive proteins were absent in the serum of non-pregnant women (data not shown). The combined densitometric values of the three vasoinhibin-like proteins were significantly higher in preeclamptic serum than in serum from normal pregnant women (Figure 2b ). In the urine, detection of 23 kDa PRL was impaired by its low concentration and interference by other proteins at and above 19 kDa. However, vasoinhibinlike proteins of 18, 16, and 14 kDa were found in the urine of preeclamptic women but not of normal pregnant (Figure 2c and d) nor of non-pregnant women (data not shown). Owing to the higher levels of PRL, AF proteins were evaluated by western blots using the N-terminal mAb without the previous immunoprecipitation step. PRL-immunoreactive proteins of 25, 23, 16, 14, 12 , and 9 kDa were detected in AF, and the smaller (o23 kDa) PRLs were more abundant in preeclamptic than in normal women (Figure 2e ). The combined densitometric values of the 25 and 23 kDa PRLs in preeclamptic AF were similar to levels in normal AF ( Figure  2f ), whereas the combined densitometric values of the 16, 14, 12, and 9 kDa vasoinhibin-like proteins were significantly higher in preeclamptic than in normal AF (Figure 2g ). 
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Vasoinhibins in Preeclamptic AF Inhibit VEGF-Induced Proliferation and NOS Activity in Endothelial Cells
To investigate further the nature of the endogenous peptides, we analyzed whether preeclamptic AF contains factors able to inhibit endothelial cell proliferation and NOS activity, two well-known effects of vasoinhibins. 14 Treatment with normal or preeclamptic AF did not affect the basal proliferation of BUVEC; however, preeclamptic AF, but not normal AF, inhibited VEGF-induced proliferation of the endothelial cells (Figure 3a) . In the absence of VEGF, normal AF stimulated NOS activity although preeclamptic AF was inactive ( Figure  3b) . Also, preeclamptic AF, but not normal AF, inhibited VEGF-induced stimulation of NOS activity (Figure 3b) . The concentration of VEGF in preeclamptic AF was lower than in normal AF (5.771.5 vs 22.3710 pg/ml; Po0.05), which might explain the lack of stimulatory effect of preeclamptic AF on basal NOS activity. However, in the presence of exogenous VEGF the inhibitory properties of preeclamptic AF indicate the presence of factors blocking the effects of VEGF.
To investigate whether vasoinhibins are responsible for the inhibitory actions of preeclamptic AF on endothelial cells, we determined the effect of anti-PRL antibodies that can neutralize vasoinhibins. These antibodies blocked the ability of the vasoinhibins standard to inhibit VEGF-induced endothelial cell proliferation and NOS activity (data not shown). Increasing concentrations of normal AF, with or without anti-PRL antibodies or control antibodies, did not modify VEGF-induced proliferation and NOS activity in BUVEC (Figure 4a and c) , whereas treatment with increasing concentrations of preeclamptic AF inhibited both actions of VEGF (Figure 4b and d) . However, the combination of preeclamptic AF and VEGF with anti-PRL antibodies, but not with control antibodies, resulted in mitogenic responses that were comparable to those observed with VEGF alone, indicating that anti-PRL antibodies block the antiangiogenic properties of preeclamptic AF (Figure 4b) . Also, anti-PRL antibodies reversed the inhibition of NOS activity by high levels of preeclamptic AF (Figure 4d ). Control antibodies had no effect on NOS activity.
Cleavage of PRL by AF and by Placental Trophoblasts
To determine if AF contains neutral proteases that are able to generate vasoinhibins from PRL, the AF of normal and preeclamptic women was incubated at pH 7 for 72 h at 371C (Figure 5a ). PRL proteolytic products were evaluated in 10 ml of AF, because the quantity of naturally occurring vasoinhibins in this volume is too low to be detected by western blots. No additional products were generated from PRL in AF incubated at pH 7, indicating the absence of proteases that can cleave PRL at the physiological pH of AF, and therefore, that vasoinhibins in the AF are likely to originate from PRL cleaved at an uteroplacental site. However, when AF was incubated at acid pH, immunoreactive bands of 14 and 8 kDa were seen (Figure 5a ). In support of cathepsin-D being the responsible protease, the generation of the 14 and the 8 kDa products at acidic pH was inhibited by the cathepsin-D inhibitor pepstatin-A (Figure 5a) . Moreover, the levels of (Figure 5b ). Incubation at acidic pH reduced the levels of PRL and its proteolytic products in normal but not in preeclamptic AF. The combined densitometric values of 23, 14, and 8 kDa PRLs were markedly reduced after acid pH incubation in normal, but not in preeclamptic AF (33.2710.7 vs 90712% of corresponding pH 7 value, respectively) ( Figure 5c ). This reduction was abolished by pepstatin-A, implicating cathepsin-D as the responsible protease. In support of the conclusion that vasoinhibins are generated by the placenta, incubation of the PRL standard with lysates from placental trophoblasts at an acidic pH, resulted in its partial conversion to fragments of 14 and 8 kDa (Figure 5d ). Cleavage was dose-dependent, and optical density values, relative to that of the control PRL band incubated in the absence of trophoblast, showed a significantly higher generation of PRL fragments by trophoblast lysates from preeclamptic patients than from normal women (Figure 5e ). Addition of pepstatin-A to the incubation mixture abolished proteolytic cleavage, indicating that cathepsin-D is the responsible enzyme (Figure 5d and e) . 
DISCUSSION
This study investigated the presence of vasoinhibins and their possible contribution to endothelial cell dysfunction and reduced birth weight in preeclampsia. We report that vasoinhibins are elevated in serum, urine, and AF of preeclamptic women and that the concentrations of vasoinhibins in AF and their antiangiogenic actions correlate with low birth weight in preeclampsia.
The role of PRL in the pathogenesis of preeclampsia was first suggested 30 years ago 26 and was recently reviewed. 27 The osmoregulatory 28 and hypertensive effects of PRL, 29, 30 together with the increased concentration of the hormone in maternal blood throughout pregnancy and its high levels in AF, 16 led investigators to propose that upregulation of PRL could contribute to hypertension associated with preeclampsia. More recently, the knowledge that defective Elevated vasoinhibins in preeclampsia C González et al placental angiogenesis is a primary event in preeclampsia, 2 and the discovery that PRL is proteolytically processed to fragments (vasoinhibins) with antiangiogenic and vasoconstrictive properties 14 strengthened the possibility that PRL is involved in this syndrome. 27 However, follow-up studies failed to show significant changes associated with preeclampsia in maternal, fetal, or AF levels of PRL as measured by radioimmunoassay 16, 31 and the presence of vasoinhibins in preeclamptic women was not examined.
Here, we confirm previous findings 16, 31 showing that the PRL concentration in serum and AF does not differ significantly between normal and preeclamptic pregnancies when measured by a non-denaturing immunoassay. Also, with this method, we determined for the first time, the levels of PRL in the urine of preeclamptic women, and found them to be similar to those of normal pregnancies. Importantly, using immunoblotting methodology, we found higher levels of PRL-immunoreactive proteins ranging from 9 to 18 kDa in all three biological fluids of preeclamptic women than of normal women. These PRLs may correspond to vasoinhibins, since they have masses similar to those reported for vasoinhibins (12-18 kDa), 14 and they react with the N-terminalspecific monoclonal antibody, suggesting that they are Nterminal fragments of the hormone. We found no evidence that vasoinhibins are present in the serum of non-pregnant women, confirming a previous observation that a 16 kDa PRL is present in the circulation of pregnant women but not of non-pregnant women. 32 It is possible that the higher levels of vasoinhibins result from the cleavage of circulating PRL, which is also high during pregnancy. A 14-kDa PRL has been detected previously in normal AF, 33 and vasoinhibins have been measured in the serum of patients with postpartum cardiomyopathy, where this vasoinhibin can cause the disease by impairing cardiac capillary network and function. 34 Since vasoinhibins have reduced immunological reactivity compared to whole, unmodified 23 kDa PRL, 35 it is possible that their larger proportion in preeclampsia is underestimated by non-denaturing immunoassays. However, their prominence in preeclampsia suggests that they are functionally linked to the disease.
Here, we show that the higher levels of vasoinhibins in preeclamptic AF result in VEGF-blocking activity. Preeclamptic AF inhibited VEGF-induced endothelial cell proliferation and NOS activity, and these actions were reversed by immunoneutralization of vasoinhibins in AF. The effect of the antibodies is consistent with the fact that vasoinhibins, and not unmodified PRL, inhibit VEGF stimulation of endothelial cell proliferation and NOS activity, 15 and that vasoinhibins, but not unmodified PRL, increase in preeclamptic AF. Recent evidence has shown that endogenous vasoinhibins suppress vasodilation and angiogenesis 36 and promote vascular regression in ocular tissues, 17 and mediate microvascular derangements in the heart. 34 However, the direct effect of vasoinhibins in systemic vascular disease has not been addressed, and the mechanisms of action of vasoinhibins are only partially known.
14 Vasoinhibins act directly on endothelial cells through a still unidentified saturable highaffinity binding site distinct from the PRL receptor, 37 and they inhibit VEGF-mediated activation of MAPK at the level of ras, 38 and can block VEGF-induced activation of endothelial NOS by the inhibition of mobilization of intracellular calcium. 15 Vasoinhibins were investigated in AF to monitor their production by the uteroplacental tissue, with the notion that their VEGF-blocking activity could contribute to defective angiogenesis in preeclampsia. Indeed, we found no evidence for neutral proteases able to cleave PRL in the AF at a physiological pH, suggesting that PRL is not cleaved in the AF but in the uteroplacental tissue instead. However, when the AF was acidified, PRL was cleaved to 14 and 8 kDa fragments. The responsible protease was cathepsin-D, since this enzyme generates similar fragments from intact human PRL, 19, 39 and the cathepsin-D inhibitor, pepstatin A, prevented the cleavage of PRL by the acidified AF. These findings indicate that endogenous cathepsin-D in AF can generate vasoinhibins from PRL, but the acidic conditions required suggest that such 
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C González et al cleavage would not occur in the AF, but in the uteroplacental tissue. Previous work indicates that cathepsin-D is expressed in the decidual-placental tissue and acidic conditions can occur locally in association with placental hypoxia in preeclampsia. 40 Indeed, our work shows that cathepsin-D from placental trophoblasts cleaves PRL to vasoinhibins and that its activity is increased in preeclampsia. In addition, the finding that PRL and vasoinhibins were more resistant to cathepsin-D-mediated degradation in preeclamptic AF than in normal AF would suggest that the elevated levels of vasoinhibins in AF from women with preeclampsia may be due to both their increased generation and reduced proteolytic degradation by placental cathepsin-D. It is unclear how cathepsin-D would efficiently cleave but not degrade PRL in preeclampsia. A possible explanation involves the absence in the preeclamptic setting of peptidases able to degrade PRL that are activated by cathepsin-D. Indeed, cathepsins activate several proteases, including matrix metalloproteases, 41 which cleave but also degrade PRL. 39 Consistent with vasoinhibins being able to interfere with placental function, we observed that the birth weight of newborns from mothers with preeclampsia correlated inversely with the concentration of PRL þ vasoinhibins in the corresponding AFs and the ability of factors present in AF to inhibit endothelial cell proliferation. These findings support antiangiogenic PRL moieties (vasoinhibins) as pivotal antiangiogenic factors in preeclamptic AF and suggest that they may contribute to the low birth weight associated with preeclampsia. Compromised actions of VEGF leading to reduced angiogenesis underlie abnormal placentation, a cause for fetal growth restriction in preeclampsia. 42 Likewise, an antiangiogenic environment during the second half of gestation may limit birth weight by reducing adipose tissue accretion in the fetus. Up to 40% of the variability in birth weight can be explained by the different amounts of adipose tissue of newborns, 43 and fetal adipose tissue mass is sensitive to angiogenesis inhibitors. 44 In contrast to inhibition of endothelial cell proliferation, there was no correlation between the weight of newborns in preeclampsia and inhibition of VEGF-induced NOS activity and PRL þ vasoinhibins concentration in AF; this observation may imply that inhibition of VEGF-induced NOS activity in preeclampsia involves factors other than vasoinhibins and that it is not an essential part of the mechanism that downregulates angiogenesis and affects fetal growth in preeclampsia. In this regard, we found that in the absence of VEGF, normal AF stimulated NOS activity but did not trigger endothelial cell proliferation. Nevertheless, NO donors increase birth weight, 45 inhibition of NO synthesis by vasoinhibins can lead to vasoconstriction, 15 a major cause for a decline in uteroplacental perfusion, 9, 11 and reduced NO levels have been reported early in pregnancy in the AF of women with subsequent preeclampsia. 8 Perhaps, if assayed before the onset of preeclampsia, inhibition of NOS activity by vasoinhibins might correlate with low birth weight. In any case, additional studies verifying the higher generation of vasoinhibins by decidual-placental tissues are needed to help understand their physiological significance for defective placentation and reduced birth weight in preeclampsia.
In conclusion, this work reports for the first time that vasoinhibins are increased in the serum, urine, and AF of preeclamptic women at the end of gestation. We propose that vasoinhibins, acting to reduce the angiogenic and vasodilating actions of VEGF, contribute to endothelial cell dysfunction and reduced birth weight in preeclampsia. Future work is required to investigate the origin of vasoinhibins associated with preeclampsia, to determine whether their concentration increases before the clinical manifestations of the disease, and to demonstrate whether these peptides are important factors for normal and altered pregnancy and birth weight.
